Piracetam
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Ischaemic Middle Cerebral Artery Stroke
Conditions
Acute Ischaemic Middle Cerebral Artery Stroke
Trial Timeline
Aug 1, 1998 → Jul 1, 2001
NCT ID
NCT01883011About Piracetam
Piracetam is a approved stage product being developed by UCB for Acute Ischaemic Middle Cerebral Artery Stroke. The current trial status is terminated. This product is registered under clinical trial identifier NCT01883011. Target conditions include Acute Ischaemic Middle Cerebral Artery Stroke.
What happened to similar drugs?
20 of 20 similar drugs in Acute Ischaemic Middle Cerebral Artery Stroke were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00567060 | Pre-clinical | Completed |
| NCT01883011 | Approved | Terminated |
Competing Products
20 competing products in Acute Ischaemic Middle Cerebral Artery Stroke